Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer

被引：15

作者：

Hong, Liu ^{[1
]}

Han, Yu ^{[2
]}

Liu, Jinqiang ^{[1
]}

Brain, Lubi ^{[3
]}

机构：

[1] Fourth Mil Med Univ, Xijing Hosp, Xijing Hosp Digest Dis, State Key Lab Canc Biol, Xian 710032, Shaanxi Provinc, Peoples R China

[2] Fourth Mil Med Univ, Xijing Hosp, Dept Otolaryngol, Xian 710032, Shaanxi Provinc, Peoples R China

[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Sch Med, Baltimore, MD 21231 USA

来源：

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY | 2013年 / 7卷 / 08期

关键词：

apoptosis; drug resistance; fibroblast growth factor; fibroblast growth factor receptor 2; gastric cancer; growth; prognosis; target; therapy; POTENT ANTITUMOR-ACTIVITY; FGFR2 GENE AMPLIFICATION; SIGNALING NETWORK; IMMUNOHISTOCHEMICAL DETECTION; K-SAM; INHIBITOR; THERAPIES; PONATINIB; KI23057;

D O I：

10.1586/17474124.2013.837804

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Gastric cancer remains a leading cause of cancer-related death in the world. FGF receptor 2 (FGFR2) is preferentially amplified and overexpressed in the diffuse type of gastric cancer. This review evaluates the expression and function of FGFR2 in gastric cancer, and analyzes the use of its inhibitors for gastric cancer therapy. This review also discusses the limitations of FGFR2-based therapy, and envisages future developments toward the clinical applications of FGFR2.

引用

页码：759 / 765

页数：7

共 46 条

[1] New targeted therapies for gastric cancer [J].

Asaoka, Yoshinari ;

Ikenoue, Tsuneo ;

Koike, Kazuhiko .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2011, 20 (05) :595-604

[2] GP369, an FGFR2-IIIb-Specific Antibody, Exhibits Potent Antitumor Activity against Human Cancers Driven by Activated FGFR2 Signaling [J].

Bai, Ailin ;

Meetze, Kristan ;

Vo, Nhi Y. ;

Kollipara, Sriram ;

Mazsa, Elizabeth K. ;

Winston, William M. ;

Weiler, Solly ;

Poling, Laura L. ;

Chen, Ting ;

Ismail, Nesreen S. ;

Jiang, Jinwei ;

Lerner, Lorena ;

Gyuris, Jeno ;

Weng, Zhigang .

CANCER RESEARCH, 2010, 70 (19) :7630-7639

[3] Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer [J].

Brooks, A. Nigel ;

Kilgour, Elaine ;

Smith, Paul D. .

CLINICAL CANCER RESEARCH, 2012, 18 (07) :1855-1862

[4]

Burbridge MF, 2013, MOL CANC THER

[5] Aberrant fibroblast growth factor receptor signaling in bladder and other cancers [J].

Chaffer, Christine L. ;

Dopheide, Bonnie ;

Savagner, Pierre ;

Thompson, Erik W. ;

Williams, Elizabeth D. .

DIFFERENTIATION, 2007, 75 (09) :831-842

[6] Neural cell adhesion molecule differentially interacts with isoforms of the fibroblast growth factor receptor [J].

Christensen, Claus ;

Berezin, Vladimir ;

Bock, Elisabeth .

NEUROREPORT, 2011, 22 (15) :727-732

[7] Current status of targeted therapies in advanced gastric cancer [J].

De Vita, Ferdinando ;

Giuliani, Francesco ;

Silvestris, Nicola ;

Rossetti, Sabrina ;

Pizzolorusso, Antonio ;

Santabarbara, Giuseppe ;

Galizia, Gennaro ;

Colucci, Giuseppe ;

Ciardiello, Fortunato ;

Orditura, Michele .

EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 :S29-S34

[8] A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets [J].

Deng, Niantao ;

Goh, Liang Kee ;

Wang, Hannah ;

Das, Kakoli ;

Tao, Jiong ;

Tan, Iain Beehuat ;

Zhang, Shenli ;

Lee, Minghui ;

Wu, Jeanie ;

Lim, Kiat Hon ;

Lei, Zhengdeng ;

Goh, Glenn ;

Lim, Qing-Yan ;

Tan, Angie Lay-Keng ;

Poh, Dianne Yu Sin ;

Riahi, Sudep ;

Bell, Sandra ;

Shi, Michael M. ;

Linnartz, Ronald ;

Zhu, Feng ;

Yeoh, Khay Guan ;

Toh, Han Chong ;

Yong, Wei Peng ;

Cheong, Hyun Cheol ;

Rha, Sun Young ;

Boussioutas, Alex ;

Grabsch, Heike ;

Rozen, Steve ;

Tan, Patrick .

GUT, 2012, 61 (05) :673-684

[9] Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy [J].

Garrett, C. R. ;

Siu, L. L. ;

El-Khoueiry, A. ;

Buter, J. ;

Rocha-Lima, C. M. ;

Marshall, J. ;

LoRusso, P. ;

Major, P. ;

Chemidlin, J. ;

Mokliatchouk, O. ;

Velasquez, L. ;

Hayes, W. ;

Feltquate, D. ;

Syed, S. ;

Ford, S. ;

Kollia, G. ;

Galbraith, S. ;

Nuyten, D. S. A. .

BRITISH JOURNAL OF CANCER, 2011, 105 (01) :44-52

[10] Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models [J].

Gozgit, Joseph M. ;

Squillace, Rachel M. ;

Wongchenko, Matthew J. ;

Miller, David ;

Wardwell, Scott ;

Mohemmad, Qurish ;

Narasimhan, Narayana I. ;

Wang, Frank ;

Clackson, Tim ;

Rivera, Victor M. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) :1315-1323

← 1 2 3 4 5 →